Raymel Hernandez
Family · Cutler Bay, FLNPI 1598307613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $64,650 of the $103,104 with a category attached, or 62.7%. 39 manufacturers reported payments, led by EMD Serono, Inc. at 29.8% of the total. 2025 is the largest year on record at $45,495, more than ten times the $1,244 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $278.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$31K
- Bayer$21K
- Johnson & Johnson$17K
- Pfizer$10K
- Astellas Pharma US Inc$9K
- Dendreon Pharmaceuticals LLC$8K
- plus $9K from 33 others
What the payments were for
- Consulting fees$8,6708%
- Speaking & faculty fees$64,65063%
- Travel & lodging$19,29319%
- Food & beverage$10,20610%
- Education$2850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 61 | $30,735 |
| Bayer | 53 | $20,687 |
| Johnson & Johnson | 47 | $16,695 |
| Pfizer | 38 | $9,802 |
| Astellas Pharma US Inc | 24 | $8,593 |
| Dendreon Pharmaceuticals LLC | 22 | $7,850 |
| Exelixis Inc. | 18 | $5,005 |
| Janssen Scientific Affairs, LLC | 1 | $563 |
| Sanofi | 7 | $442 |
| Seagen Inc. | 4 | $355 |
| Eisai Inc. | 12 | $328 |
| Novartis | 11 | $228 |
| Jazz Pharmaceuticals Inc. | 2 | $201 |
| Sun Pharmaceutical Industries Inc. | 8 | $158 |
| Daiichi Sankyo Inc. | 3 | $131 |
| AstraZeneca | 5 | $117 |
| Taiho Oncology, Inc. | 6 | $106 |
| Incyte Corporation | 5 | $103 |
| Genentech USA, Inc. | 2 | $101 |
| Gilead | 1 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Merck | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Servier Pharmaceuticals LLC | 3 | $74 |
| AVEO Pharmaceuticals, Inc. | 2 | $56 |
| Deciphera Pharmaceuticals Inc. | 2 | $50 |
| Beone Medicines USA, Inc. | 3 | $49 |
| Beigene USA, Inc. | 2 | $35 |
| Sobi, Inc | 1 | $34 |
| Coherus Oncology, Inc. | 2 | $34 |
| Tersera Therapeutics LLC | 1 | $33 |
| Tolmar, Inc. | 2 | $31 |
| Immunocore Limited | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Pharmaand GmbH | 3 | $27 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $21 |
| Caris MPI, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,104 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 58 | $1,824,828 |
| Abiraterone Acetate | 389 | $735,625 |
| XtandiEnzalutamide | 52 | $709,791 |
| ErleadaApalutamide | 40 | $592,868 |
| NubeqaDarolutamide | 45 | $557,428 |
| InlytaAxitinib | 22 | $420,266 |
| FotivdaTivozanib Hcl | 11 | $332,135 |
| LynparzaOlaparib | 14 | $226,350 |
| OrgovyxRelugolix | 25 | $70,767 |
| Prednisone | 215 | $1,492 |
| Dexamethasone | 13 | $511 |
| Bicalutamide | 23 | $387 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $385 |
| Prochlorperazine Maleate | 40 | $326 |
| Ondansetron Hcl | 28 | $228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $5,005 | $1,824,82858 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $563 | $735,625389 claims |
| Astellas Pharma US IncXtandi | $8,593 | $709,79152 claims |
| Johnson & JohnsonErleada | $16,695 | $592,86840 claims |
| BayerNubeqa | $20,687 | $557,42845 claims |
| PfizerInlyta | $9,802 | $420,26622 claims |
| AstraZenecaLynparza | $117 | $226,35014 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $28 | $70,76725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Cutler Bay
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.